Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Tarpeyo Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Tarpeyo Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Commercial coverage of Tarpeyo (budesonide delayed-release 4 mg capsules) for patients with primary immunoglobulin A nephropathy at risk for disease progression, subject to clinical criteria, specialist involvement or consultation, contraindication screening, and quantity-limit requirements.

    Policy Summary
    PayerPrime Therapeutics
    PolicyTarpeyo Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateSep 15, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming biopsy-proven primary IgA nephropathy, disease-progression risk, qualifying proteinuria, eGFR of at least 30 mL/min/1.73 m², applicable therapy history, specialist involvement, and no Tarpeyo contraindications.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    10 monthsApproval duration
    ≥30 mL/min/1.73 m²Minimum eGFR
    ≥0.44 g/gUPCR threshold
    ≥0.5 g/dayProteinuria threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    9 months
    Prior Tarpeyo course
    4 mg capsuleDosage form

    Coverage Criteria

    Initial and repeat therapy approval

    Covered when all of the following are met.

    Clinical approval criteria

    • Diagnosis and treatment purpose: The patient has primary immunoglobulin A nephropathy confirmed by kidney biopsy, and the requested agent will be used to reduce loss of kidney function in a patient at risk for disease progression.
    • Proteinuria threshold

      • UPCR criterion: Urine protein-to-creatinine ratio is at least 0.44 g/g.≥0.44 g/g
      • Proteinuria criterion: Proteinuria is at least 0.5 g/day.≥0.5 g/day
    • Kidney function: The patient's eGFR is at least 30 mL/min/1.73 m².≥30 mL/min/1.73 m²
    • ACE inhibitor or ARB pathway: One of the following must apply: the patient uses an ACE inhibitor, angiotensin II blocker, or combination medication containing an ACE inhibitor or ARB; has an intolerance or hypersensitivity to an ACE inhibitor or ARB; or has an FDA-labeled contraindication to all ACE inhibitors and ARBs.

      Examples include benazepril, lisinopril, and losartan.

    • Oral glucocorticoid pathway: One of the following must apply: the patient has an intolerance or hypersensitivity to one oral generic glucocorticoid that is not expected to occur with Tarpeyo, or has an FDA-labeled contraindication to all oral generic glucocorticoids that is not expected to occur with Tarpeyo.

      Chart notes are required for these exceptions.

    • Treatment-course status: Either the patient has not previously been treated with a 9-month course of Tarpeyo, or the patient previously completed a course and there is support for an additional course.9 months
    • Prescriber qualification: The prescriber is a specialist in the area of the patient's diagnosis, such as a nephrologist, or has consulted with such a specialist.
    • Requested-agent safety: The patient does not have any FDA-labeled contraindications to Tarpeyo.
    Approval duration: When approved, authorization is granted for 10 months.10 months

    Quantity-limit criteria may also apply.

    Quantity-limit approval

    A quantity-limit exception is approved when either the requested quantity is within the program limit or an applicable exception pathway is met.

    • Within limit: The requested quantity does not exceed the program quantity limit.
    • Exception pathways

      • No maximum FDA-labeled dose: The requested agent does not have a maximum FDA-labeled dose for the requested indication, and there is support for therapy with a higher dose for the requested indication.
      • Within maximum dose but quantity cannot be achieved otherwise: The requested quantity does not exceed the maximum FDA-labeled dose for the requested indication, and there is support for why the requested quantity cannot be achieved with a lower quantity of a higher strength that does not exceed the program quantity limit.

    Tarpeyo is excluded from approval when the patient has any FDA-labeled contraindication to the requested agent.

    Initial Therapy

    Initial therapy

    Initial therapy is approved when all clinical criteria are met.

    Initial Tarpeyo therapy

    • Diagnosis and treatment purpose: The patient has primary immunoglobulin A nephropathy confirmed by kidney biopsy, and Tarpeyo will be used to reduce loss of kidney function in a patient at risk for disease progression.
    • Proteinuria threshold

      • UPCR criterion: Urine protein-to-creatinine ratio is at least 0.44 g/g.≥0.44 g/g
      • Proteinuria criterion: Proteinuria is at least 0.5 g/day.

    Continuation and Additional Therapy

    Additional Tarpeyo course

    For a patient previously treated with Tarpeyo, continuation or an additional course requires support for the additional course.

    Additional course: The patient was previously treated with a 9-month course of Tarpeyo and there is support for an additional course of therapy with Tarpeyo.9 months

    Clinical Thresholds and Course Parameters

    Urine protein-to-creatinine ratio
    MeasureUrine protein-to-creatinine ratio (UPCR)
    Required threshold≥0.44 g/g
    Criteria pathwayOne of the required proteinuria thresholds
    Proteinuria
    MeasureProteinuria
    Required threshold≥0.5 g/day
    Criteria pathwayAlternative to the UPCR threshold

    Submission and Approval Requirements

    Prior Authorization

    Clinical Prior Authorization Required

    Prior authorization is required. Approval requires that all clinical criteria for Tarpeyo be documented and met. Approved coverage is limited to a 10-month period.

    • Biopsy-confirmed primary immunoglobulin A nephropathy (IgAN).
    • Use to reduce loss of kidney function in a patient at risk for disease progression.
    • UPCR is ≥ 0.44 g/g or proteinuria is ≥ 0.5 g/day.
    • eGFR is ≥ 30 mL/min/1.73 m².
    • The patient meets the ACE inhibitor/ARB prerequisite or an allowed exception.
    • The patient meets an allowed glucocorticoid exception, if applicable; chart notes are required.
    • The patient has not previously completed a 9-month course of the requested agent, or support exists for an additional course.
    • The prescriber is a relevant specialist, such as a nephrologist, or has consulted with one.
    • The patient has no FDA-labeled contraindication to the requested agent.

    Policy Background

    This policy addresses commercial coverage of Tarpeyo (budesonide delayed-release 4 mg capsules) for patients with primary immunoglobulin A nephropathy (IgAN) confirmed by kidney biopsy who are at risk for progressive loss of kidney function. Coverage evaluation considers disease-progression risk, proteinuria, kidney function, relevant prior or concomitant therapy, specialist involvement, and Tarpeyo safety requirements.

    Step-Therapy Requirement

    StepRequired therapyApplicable exceptions
    1
    Use an ACE inhibitor, angiotensin II receptor blocker (ARB), or a combination medication containing an ACE inhibitor or ARB.
    Intolerance or hypersensitivity to an ACE inhibitor or ARB; or an FDA-labeled contraindication to all ACE inhibitors and ARBs.

    Program Quantity Limit

    Tarpeyo quantity limit
    Covered agentTarpeyo
    Strength4 mg
    Dosage formBudesonide delayed-release capsule
    Program limitQuantity limit applies per month; the numeric quantity amount is not specified in the source text
    Day supply reference30 days
    Policy Summary
    PayerPrime Therapeutics
    PolicyTarpeyo Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateSep 15, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming biopsy-proven primary IgA nephropathy, disease-progression risk, qualifying proteinuria, eGFR of at least 30 mL/min/1.73 m², applicable therapy history, specialist involvement, and no Tarpeyo contraindications.
    SourceLink
    On This Page
    Coverage CriteriaInitial TherapyContinuation and Additional TherapyClinical Thresholds and Course ParametersSubmission and Approval RequirementsPolicy BackgroundStep-Therapy RequirementProgram Quantity Limit
    Above maximum dose with support: The requested quantity exceeds the maximum FDA-labeled dose for the requested indication, and there is support for therapy with a higher dose for the requested indication.
    ≥0.5 g/day
  1. Kidney function: The patient's eGFR is at least 30 mL/min/1.73 m².≥30 mL/min/1.73 m²
  2. ACE inhibitor or ARB pathway: One of the following must apply: the patient uses an ACE inhibitor, angiotensin II blocker, or combination medication containing an ACE inhibitor or ARB; has an intolerance or hypersensitivity to an ACE inhibitor or ARB; or has an FDA-labeled contraindication to all ACE inhibitors and ARBs.

    Examples include benazepril, lisinopril, and losartan.

  3. Oral glucocorticoid pathway: One of the following must apply: the patient has an intolerance or hypersensitivity to one oral generic glucocorticoid that is not expected to occur with Tarpeyo, or has an FDA-labeled contraindication to all oral generic glucocorticoids that is not expected to occur with Tarpeyo.

    Chart notes are required for these exceptions.

  4. No prior 9-month Tarpeyo course: The patient has not previously been treated with a 9-month course of Tarpeyo.9 months
  5. Prescriber qualification: The prescriber is a specialist in the area of the patient's diagnosis, such as a nephrologist, or has consulted with such a specialist.
  6. Requested-agent safety: The patient does not have any FDA-labeled contraindications to Tarpeyo.
  7. Estimated glomerular filtration rate
    MeasureEstimated glomerular filtration rate (eGFR)
    Minimum criterion≥30 mL/min/1.73 m²
    ApplicationRequired kidney-function threshold for approval
    Prior requested-agent course
    Requested-agent courseTarpeyo course of therapy
    Referenced duration9 months
    Additional-course pathwayA patient previously treated with a 9-month course may qualify for an additional course when support is provided
    Step Therapy

    ACE Inhibitor or ARB Prerequisite

    Document prior therapy with an ACE inhibitor, an angiotensin II receptor blocker (ARB), or a combination medication containing an ACE inhibitor or ARB, unless an allowed exception applies.

    • Required prerequisite: prior treatment with an ACE inhibitor (for example, benazepril or lisinopril), an ARB (for example, losartan), or a combination product containing an ACE inhibitor or ARB.
    • Permitted exceptions: intolerance or hypersensitivity to an ACE inhibitor or ARB, or an FDA-labeled contraindication to all ACE inhibitors and ARBs.
    Documentation Required

    Clinical Records Supporting Approval

    Submit clinical records that substantiate the diagnosis, disease risk, renal function, and treatment rationale. Records should allow the plan to verify every applicable clinical approval threshold.

    • Kidney biopsy confirming primary IgAN.
    • Documentation that treatment is intended to reduce loss of kidney function in a patient at risk for disease progression.
    • UPCR result of ≥ 0.44 g/g or proteinuria of ≥ 0.5 g/day.
    • eGFR result of ≥ 30 mL/min/1.73 m².
    • ACE inhibitor/ARB treatment history or documentation of an allowed exception.
    • Requested-agent treatment history, including whether a 9-month course was completed and, when applicable, support for an additional course.
    • Prescriber specialty or documentation of consultation with a specialist in the area of diagnosis.
    • Review of FDA-labeled contraindications to the requested agent.
    Documentation Required

    Chart Notes Required for Glucocorticoid Exceptions

    For an exception based on glucocorticoid intolerance, hypersensitivity, or contraindication, submit chart notes supporting the exception and explaining why it is not expected to occur with the requested agent.

    • Document intolerance or hypersensitivity to one oral generic glucocorticoid, with chart notes required.
    • Alternatively, document an FDA-labeled contraindication to all oral generic glucocorticoids, with chart notes required.
    • The documented reaction or contraindication must not be expected to occur with the requested agent.
    Documentation Required

    Quantity-Limit Exception Documentation

    When the requested quantity exceeds the program quantity limit, submit documentation supporting the applicable quantity-limit exception. Approval of an excess quantity requires that one complete exception pathway be met.

    • If there is no maximum FDA-labeled dose for the indication, document that the higher dose is supported for the indication.
    • If the request does not exceed the maximum FDA-labeled dose, document why the requested quantity cannot be achieved with a lower quantity of a higher strength that remains within the program quantity limit.
    • If the request exceeds the maximum FDA-labeled dose, document support for therapy with the higher dose for the indication.
    Denial Risk

    Failure to Meet Clinical Approval Criteria

    Failure to satisfy any required clinical approval criterion may result in denial of the request. Ensure the submission clearly supports the diagnosis, clinical thresholds, prerequisite therapy or exception, treatment history, specialist involvement, and absence of contraindications.

    • No biopsy-confirmed primary IgAN or no documented risk of progressive kidney-function loss.
    • UPCR, proteinuria, or eGFR does not meet the required threshold.
    • ACE inhibitor/ARB prerequisite is not met and no permitted exception is documented.
    • Required glucocorticoid exception documentation is absent or does not support the exception.
    • The requested agent has already been used for 9 months without support for an additional course.
    • The prescriber is not a relevant specialist and specialist consultation is not documented.
    • The patient has an FDA-labeled contraindication to the requested agent.
    Denial Risk

    Excess Quantity Without an Approved Exception

    A request for a quantity above the program limit may be denied when the submission does not document an approved quantity-limit exception.

    • The requested quantity exceeds the program quantity limit.
    • No applicable exception pathway is supported: higher-dose therapy without a maximum labeled dose, inability to use a lower quantity of a higher strength within the limit, or support for a dose above the maximum labeled dose.